News

May 12, 2024 | BALTIMORE –  Complete Omics is thrilled to announce that our Valid-NEO^® platform’s “Method and System for Neoantigen Analysis” has been granted a U.S. patent after a rigorous three-year review by the USPTO. This breakthrough makes Valid-NEO^® the only patented method in the U.S. capable of directly quantifying neoantigens on cell surfaces. This milestone underscores the platform’s significant technical value, setting it apart in the neoantigen detection field.

Valid-NEO^® has revolutionized the market with its ability to overcome traditional challenges in cancer-related gene mutation analysis. By directly and accurately detecting neoantigens with high sensitivity and specificity, Valid-NEO^® allows for absolute quantification and precise analysis at the single-cell level, requiring minimal sample amounts. This makes it a game-changer in personalized medicine and drug development, offering unparalleled accuracy in identifying neoantigen sequences and their immunogenicity.

In practice, Valid-NEO^® supports both innovative drug development and companion diagnostics, helping pharmaceutical companies identify patients suitable for clinical trials and aiding in personalized treatment planning. Unlike traditional gene sequencing combined with AI algorithms, Valid-NEO^® offers superior sensitivity by directly reading data from cell surfaces, making it a core technology in identifying tumor neoantigen targets and enhancing cancer immunotherapy.

We are immensely proud of this achievement and its implications for the future of cancer treatment. Valid-NEO^® not only advances neoantigen detection but also deepens the application of personalized medicine in oncology. We believe this patented technology will drive the development of new drugs and therapies targeting tumor neoantigens, accelerating the realization of more universal personalized cancer immunotherapy solutions.

For detailed case studies on Valid-NEO^® applications, please refer to our publications:

1. “Targeting a neoantigen derived from a common TP53 mutation,” Science, 2021.
2. “Bispecific antibodies targeting mutant RAS neoantigens,” Science Immunology, 2021.
3. “Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy,” Science Advances, 2022.